C-Path is proud to share our responses to the FDA draft guidance, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations
The Clinical Outcomes Assessment (COA), Critical Path for Parkinson’s Digital Drug Development (3DT) Initiative, and Type 1 Diabetes (T1D) Consortia all contributed to this effort, resulting in a combined set of comments on behalf of C-Path. By bringing together stakeholders across industry, regulatory agencies, patient groups, academic researchers and clinicians, disease foundations and other organizations aiming to improve patients’ lives, C-Path hopes these comments will provide helpful feedback on how DHT (Digital Health Technologies) are used to accelerate a path to a healthier world.
We thank and commend FDA for the opportunity to provide comments and look forward to future developments in this area.
Digital Health Technologies for Remote Data Acquisition in Clinical Investigations